RS-2023-00284156

Non-clinical study completion and manufacturing system development of CX301 for the development of orphan drug on malignant ischemic stroke

Cenyx Biotech Inc.

NEUROSCIENCE | **Preclinical**

Product Type	Cerium oxide-based polymer-incorporated nanozyme, CX301
Indication	Malignant/massive ischemic stroke (MIS)
Target	ROS-related inflammation
MoA(Mechanism of Action)	A multipotent and powerful cerium oxide nanozyme – ROS (reactive oxygen species) scavenging antioxidant actions on hot spots of nanozyme surface
Competitiveness	- **CX301**: First-in-class and First-in-human ceria nanozyme drug - No approved drugs in MIS practice and market: no actual competitors of CX301 - The table delineates neuroprotective agents for ischemic stroke that do not pertain to MIS
Development Stage	Preclinical
Route of Administration	Intravenous

Drug	Company	Status
Edaravone	Mitsubishi	Approved only in Japan
Nerinetide	NoNO	Failed phase 3 clinical trials
ApTOLL	AptaTargets	Completed phase 1B/2A in Europe

kddf_bd@kddf.org
KDDF Business Development Team

KDDF Korea Drug Development Fund